A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder.

Neurol Ther · 2026 · PMC13172088 · PMID 41795763

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

nominally significantp < 0.05actually significant

For nominally significant interactions (unadjusted p < 0.05), we reported estimates reflecting differences in treatment responses between clinical subgroups (Table 3 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.